LLY · News · 20261031N

Market Demand - Anti-Obesity

ELI LILLY & Co · 2026-10-31 · Importance 26 · Surprise 24

The report attributes Eli Lilly’s strong third-quarter results to surging demand for its obesity and diabetes treatments. It names Mounjaro and Zepbound as the products driving that demand. No market-size, order, or geographic demand data is provided.

Key facts